Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cameron Health’s Subcutaneous ICD Gains FDA Panel Endorsement

This article was originally published in The Gray Sheet

Executive Summary

Following the panel vote April 26, Cameron CEO Kevin Hykes told “The Gray Sheet” that the company expects to receive PMA approval in the first half of 2013, as previously anticipated.

You may also be interested in...

Subcutaneous ICD Matches Standard ICD In Controlled Trial

Short-term results in a study of Boston Scientific's S-ICD device show promise, but also point to room for improvement.

New Products In Brief

Recent new product launches and approvals include Boston Scientific’s novel S-ICD subcutaneous implantable cardioverter defibrillator, Globus Medical’s Secure-C artificial cervical disc and ConforMIS’ next-generation iTotal G2 total knee replacement.

Boston Scientific Buys Cameron Health For First Subcutaneous ICD

Deal includes $150 million up front, but is worth up to $1.35 billion with potential milestone payments.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts